3D Bioprinting Market Size, Share & Trends Analysis Report By Technology (Magnetic Levitation, Inkjet Based, Syringe Based, Laser Based), By Application, And Segment Forecasts, 2018 - 2024

Industry Insight

The global 3D Bioprinting market size was valued at USD 682 million in 2016 and is expected to witness a CAGR of 18.4% over the forecast period. The growth is attributed to rising incidences of chronic illnesses leading to organ and tissue transplants coupled with increasing life span of individuals and limited number of organ donors.

Advancement in technology and incorporation of IT within the healthcare industry, rising geriatric population base and improving R&D efforts for the sector act as high impact rendering drivers for this market. As of 2015, numerous universities and research institutes are analyzing the prospects of bio-printed implants, organs and tissue reconstructions. For instance, the Heriot-Watt University of Scotland created a 3D bio-printer that is capable of printing pluripotent stem cell cultures that may be applied for drug testing.

The bioprinting technology can be used in the creation of prosthetic limbs and skin grafts. The 3D printer using nanotechnology can print these live skin-based organs in hours. There has been a plenty of research going on in this field. The overall cost-reduction, increased efficiency, and products with better stability are the focal areas of interest in the R&D. For instance, 3D printing using graphene, which has a high level of strength than plastic yielded more comfortable and durable prosthetics.

The increasing prevalence of cancer is one of the key factors attributing for the growth of market. For instance, 3D printing of biomimetic microstructure can be used for cancer cell migration studies. According to the data published by the WHO, it has been estimated that in 2012, worldwide cancer incidences (cases per year) were nearly 14.1 Million, which include 7.4 million male and 6.7 million female patients.

Presence of large population above 60 years, who have low immunity levels and are prone to neurological diseases, cardiac problems, cancers and spinal injuries, and thereby is a high impact-rendering driver for the growth of 3D bioprinting market over the forecast period. This population is expected to avail the latest treatments, which increase their life span. Furthermore, innovative and low-cost technologies in are set to disrupt the market and increase usage rate of bio-printed products over the forecast period of seven years

Technology Insights

On the basis of technology used for the printing of biological materials, the 3D bioprinting market has been segmented into magnetic levitation, inkjet-based 3D bioprinting, syringe-based 3D bioprinting, laser-based 3D bioprinting, and others.

Magnetic levitation is anticipated to witness the fastest growth over the forecast period, whereas syringe-based 3D bioprinting is expected to be the largest market. The broad application and rising adoption of this technique by researchers is a factor that promotes the growth of magnetic levitation. Furthermore, printers working on this principle are comparatively cheaper than the other products, thereby boosting the growth.

The next generation magnetic levitation 3D bio-printers are expected to solve more that 80% of the current failures encountered along with enhanced speed and precision. Magnetic levitation printers find application in toxicity screening, vascular smooth muscle printing, human cell generation and their drug response management.

BioAssay is a company dealing with manufacturing of tissue-like structure which makes use of these printers on a large scale to benefit from magnetic levitation technology.

Application Insights

Key applications analyzed in the study include dental, medical, biosensors, bioinks, food and animal product bioprinting and consumer/personal product testing. The medical segment is expected to dominate the market with over 30.0% share in 2022 and cover the regeneration of organs, tissues, implants and prosthetics along with medical pill production.

Medical pills are the latest development in the 3D bioprinting market and are expected to witness lucrative growth over the forecast period. This growth may be attributed to the increasing need of medicines and the advantage of fast and cost-efficient production of biodrugs using 3D bioprinting. According to various industry experts, the pharmaceutical industry is expected to grow multi-folds, thereby increasing the volume of medical pill production.

Aprecia Pharmaceuticals received the first ever U.S. FDA approval for 3D printing of their drug Spritam in August 2015. The drug would have therapeutic action in treatment of epileptic patients

Regional Insights

North America is anticipated to dominate the global market in terms of revenue over the forecast period. It held over 35.0% of the market share as of 2014 is expected to grow at CAGR of over 10.0%. Presence of a huge geriatric and chronically ill population within the region coupled with refined healthcare infrastructure and reasonably higher patient disposable income levels are the key drivers of this market.

Furthermore, extensive research activities currently conducted within the region are expected to be vital growth factor over the forecast period. The Wake Forest University of North Carolina presented their research for development of customized medication at the American Heart Association Scientific Sessions (AHASS) in November 2015. The pills would be designed according to the biological profile of each patient which includes, organ function capacity, weight, gender and race.

Asia Pacific is expected to witness lucrative growth owing to their pioneering presence in development of healthcare IT and quick adaption of technological advancements. Furthermore, rising awareness level, increasing foreign investments within the region for the purpose of research and supportive government initiatives is expected to propel this development over the next seven years.

3D Bioprintings Market Share Insights

Key players operating in the 3D bioprinting industry include Organovo Holding Inc., Cyfuse Biomedical, BioBots, Luxexcel Group BV, TeVido BioDevices, Aspect Biosystems, 3Dynamics Systems, Stratasys Ltd., Voxeljet, Oceanz, Materialise NV, Envision TEC, Bio3D Technologies, Solidscape and others.

Most of the market players have formed tie-ups with research institutes and universities that work on grafting and organ regeneration technologies. Also, the players are scheduling various exhibitions and seminars in order to raise awareness regarding the industry globally.

Organovo Holding Inc. announced a partnership with hair and skin care L’Oreal to develop skin tissue using their NovoGen Bioprinting Platform.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels as well as provides an analysis on the latest trends and opportunities in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global 3D Bioprinting market report on the basis of technology, application, and region:

• Technology Type Outlook (Revenue, USD Million, 2012 - 2024)

  • Magnetic Levitation

  • Inkjet based 3D bioprinting

  • Syringe based 3D bioprinting

  • Laser based 3D bioprinting

  • Others

• Application Type Outlook (Revenue, USD Million, 2012 - 2024)

  • Medical

  • Dental

  • Biosensors

  • Consumer/Personal product testing

  • Bioinks

  • Food and animal product bioprinting

• Regional Outlook (Revenue, USD Million, 2012 - 2024)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • MEA

    • South Africa